104 results on '"Love CJ"'
Search Results
2. Long term complications in patients implanted with subcutaneous implantable defibrillators real-world data from the Extended ELISIR experience
- Author
-
Gasperetti, A, Schiavone, M, Ziacchi, M, Vogler, J, Breitenstein, A, Laredo, M, Palmisano, P, Ricciardi, D, Mitacchione, F, Compagnucci, P, Bisignani, A, Angeletti, A, Casella, M, Picarelli, F, Fink, T, Kaiser, L, Hakmi, S, Calò, L, Pignalberi, C, Santini, L. ì., Lavalle, C, Pisanòe, Olivotto, I, Tondo, C, Curnis, A, Russo, Ad, Badenco, N, Steffeli, J, Love, Cj, Tilz, R, Forleo, G, and Biffi, M.
- Published
- 2021
3. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations.
- Author
-
Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, Hayes DL, Howlett JG, Kautzner J, Love CJ, Morgan JM, Priori SG, Reynolds DW, Schoenfeld MH, Vardas PE, Heart Rhythm Society, Wilkoff, Bruce L, Auricchio, Angelo, Brugada, Josep, and Cowie, Martin
- Published
- 2008
- Full Text
- View/download PDF
4. HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations: developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Failure Society of America (HFSA). Endorsed by the Heart Rhythm Society, the European Heart Rhythm Association (a registered branch of the ESC), the American College of Cardiology, the American Heart Association.
- Author
-
Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, Hayes DL, Howlett JG, Kautzner J, Love CJ, Morgan JM, Priori SG, Reynolds DW, Schoenfeld MH, Vardas PE, and Heart Rhythm Society (HRS)
- Published
- 2008
- Full Text
- View/download PDF
5. Intravascular extraction of problematic or infected permanent pacemaker leads: 1994-1996.
- Author
-
Byrd CL, Wilkoff BL, Love CJ, Sellers TD, Turk KT, Reeves R, Young R, Crevey B, Kutalek SP, Freedman R, Friedman R, Trantham J, Watts M, Schutzman J, Oren J, Wilson J, Gold F, Fearnot NE, and Van Zandt HJ
- Abstract
Of the 400,000-500,000 permanent pacemaker leads implanted worldwide each year, around 10% may eventually fail or become infected, becoming potential candidates for removal. Intravascular techniques for removing problematic or infected leads evolved over a 5-year period (1989-1993). This article analyzes results from January 1994 through April 1996, a period during which techniques were fairly stable. Extraction of 3,540 leads from 2,338 patients was attempted at 226 centers. Indications were: infection (27%), nonfunctional or incompatible leads (25%), Accufix(R) or Encor(R) leads (46%), or other causes (2%). Patients were 64 ± 17 years of age (range 5-96); 59% were men, 41% women. Leads were implanted 47 ± 41 months (maximum 26 years), in the atrium (53%), ventricle (46%), or SVC (1 %). Extraction was attempted via the implant vein using locking stylets and dilator sheaths, and/or transfemorally using snares, retrieval baskets, and sheaths. Complete removal was achieved for 93% of leads, partial for 5%, and 2% were not removed. Risk of incomplete or failed extraction increased with implant duration (P < 0.0001), less experienced physicians (P < 0.0001), ventricular leads (P < 0.005), noninfected patients (P < 0.0005), and younger patients (P < 0.0001). Major complications were reported for 1.4% of patients (< 1% at centers with > 300 cases), minor for 1.7%. Risk of complications increased with number of leads removed (P < 0.005) and with less experienced physicians (P < 0.005); risk of major complications was higher for women (P < 0.01). Given physician experience, appropriate precautions, and appropriate patient selection, contemporary lead removal techniques allow success with low complication rates. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
6. To the editor.
- Author
-
Mehta R and Love CJ
- Published
- 2007
- Full Text
- View/download PDF
7. Should they stay or should they go? Stroke transfers across a hospital network pre- and post-implementation of an automated image interpretation and communication platform.
- Author
-
Bonner J, Love CJ, Bhat V, and Siegler JE
- Abstract
Background: A key decision facing nonthrombectomy capable (spoke) hospitals is whether to transfer a suspected large vessel occlusion (LVO) patient to a comprehensive stroke center (CSC). In a retrospective cohort study, we investigated the rate of transfers resulting in endovascular thrombectomy (EVT) and associated costs before and after implementation of an artificial intelligence (AI)-based software., Methods: All patients with a final diagnosis of acute ischemic stroke presenting across a five-spoke community hospital network in affiliation with a CSC were included. The Viz LVO (Viz.ai, Inc.) software was implemented across the spokes with image sharing and messaging between providers across sites. In a cohort of patients before (pre-AI, December 2018-October 2020) and after (post-AI, October 2020-August 2022) implementation, we compared the EVT rate among ischemic stroke patients transferred out of our health system to the CSC. Secondary outcomes included the EVT rate based on spoke computed tomography angiography (CTA) and estimated transfer costs., Results: A total of 3113 consecutive eligible patients (mean age 71 years, 50% female) presented to the spoke hospitals with 162 transfers pre-AI and 127 post-AI. The rate of transfers treated with EVT significantly increased (32.1% pre-AI vs. 45.7% post-AI, p = 0.02). There was a sharp increase in CTA use post-AI at the spoke hospitals for all patients and transfers that likely contributed to the increased EVT transfer rate, but prior spoke CTA use alone was not sufficient to account for all improvement in EVT transfer rate (37.2% pre-AI vs. 49.2% post-AI, p = 0.12). In a binary logistic regression model, the odds of an EVT transfer in the intervention period were 1.85 greater as compared to preintervention (adjusted odds ratio 1.85, 95% confidence interval 1.12-3.06). The decrease in non-EVT transfers resulted in an estimated annual benefit of $206,121 in spoke revenue and $119,921 in payor savings (all US dollars)., Conclusions: The implementation of an automated image interpretation and communication platform was associated with increased CTA use, more transfers treated with EVT, and potential economic benefits., Competing Interests: Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CJL discloses employment with Viz.ai.
- Published
- 2024
- Full Text
- View/download PDF
8. Male autism spectrum disorder is linked to brain aromatase disruption by prenatal BPA in multimodal investigations and 10HDA ameliorates the related mouse phenotype.
- Author
-
Symeonides C, Vacy K, Thomson S, Tanner S, Chua HK, Dixit S, Mansell T, O'Hely M, Novakovic B, Herbstman JB, Wang S, Guo J, Chia J, Tran NT, Hwang SE, Britt K, Chen F, Kim TH, Reid CA, El-Bitar A, Bernasochi GB, Delbridge LMD, Harley VR, Yap YW, Dewey D, Love CJ, Burgner D, Tang MLK, Sly PD, Saffery R, Mueller JF, Rinehart N, Tonge B, Vuillermin P, Ponsonby AL, and Boon WC
- Subjects
- Animals, Male, Female, Pregnancy, Mice, Humans, Phenotype, Disease Models, Animal, Promoter Regions, Genetic, Child, Preschool, Aromatase metabolism, Aromatase genetics, Autism Spectrum Disorder genetics, Autism Spectrum Disorder chemically induced, Benzhydryl Compounds toxicity, Phenols toxicity, Brain drug effects, Brain metabolism, Prenatal Exposure Delayed Effects, DNA Methylation drug effects, Mice, Knockout
- Abstract
Male sex, early life chemical exposure and the brain aromatase enzyme have been implicated in autism spectrum disorder (ASD). In the Barwon Infant Study birth cohort (n = 1074), higher prenatal maternal bisphenol A (BPA) levels are associated with higher ASD symptoms at age 2 and diagnosis at age 9 only in males with low aromatase genetic pathway activity scores. Higher prenatal BPA levels are predictive of higher cord blood methylation across the CYP19A1 brain promoter I.f region (P = 0.009) and aromatase gene methylation mediates (P = 0.01) the link between higher prenatal BPA and brain-derived neurotrophic factor methylation, with independent cohort replication. BPA suppressed aromatase expression in vitro and in vivo. Male mice exposed to mid-gestation BPA or with aromatase knockout have ASD-like behaviors with structural and functional brain changes. 10-hydroxy-2-decenoic acid (10HDA), an estrogenic fatty acid alleviated these features and reversed detrimental neurodevelopmental gene expression. Here we demonstrate that prenatal BPA exposure is associated with impaired brain aromatase function and ASD-related behaviors and brain abnormalities in males that may be reversible through postnatal 10HDA intervention., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
9. LINE-1 retrotransposons contribute to mouse PV interneuron development.
- Author
-
Bodea GO, Botto JM, Ferreiro ME, Sanchez-Luque FJ, de Los Rios Barreda J, Rasmussen J, Rahman MA, Fenlon LR, Jansz N, Gubert C, Gerdes P, Bodea LG, Ajjikuttira P, Da Costa Guevara DJ, Cumner L, Bell CC, Kozulin P, Billon V, Morell S, Kempen MHC, Love CJ, Saha K, Palmer LM, Ewing AD, Jhaveri DJ, Richardson SR, Hannan AJ, and Faulkner GJ
- Subjects
- Animals, Mice, Retroelements genetics, Male, Neurogenesis physiology, Neurogenesis genetics, Mice, Inbred C57BL, Gene Expression Regulation, Developmental genetics, Interneurons metabolism, Interneurons physiology, Long Interspersed Nucleotide Elements genetics, Parvalbumins metabolism
- Abstract
Retrotransposons are mobile DNA sequences duplicated via transcription and reverse transcription of an RNA intermediate. Cis-regulatory elements encoded by retrotransposons can also promote the transcription of adjacent genes. Somatic LINE-1 (L1) retrotransposon insertions have been detected in mammalian neurons. It is, however, unclear whether L1 sequences are mobile in only some neuronal lineages or therein promote neurodevelopmental gene expression. Here we report programmed L1 activation by SOX6, a transcription factor critical for parvalbumin (PV) interneuron development. Mouse PV interneurons permit L1 mobilization in vitro and in vivo, harbor unmethylated L1 promoters and express full-length L1 mRNAs and proteins. Using nanopore long-read sequencing, we identify unmethylated L1s proximal to PV interneuron genes, including a novel L1 promoter-driven Caps2 transcript isoform that enhances neuron morphological complexity in vitro. These data highlight the contribution made by L1 cis-regulatory elements to PV interneuron development and transcriptome diversity, uncovered due to L1 mobility in this milieu., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
10. Taurolidine: could this be the 'silver bullet' against cardiac implantable electronic device infection?
- Author
-
Love CJ
- Subjects
- Humans, Electronics, Thiadiazines, Defibrillators, Implantable adverse effects, Heart Diseases, Anti-Infective Agents
- Abstract
Competing Interests: Conflict of interest: C.J.L. discloses that he serves as a medical advisor to Medtronic, Philips, Eximo, and Xcardia and receives research funding and speaking honoraria: Boston Scientific. He has no financial interest in TauroPharm.
- Published
- 2023
- Full Text
- View/download PDF
11. Preclinical evaluation of a third-generation absorbable antibacterial envelope.
- Author
-
Love CJ, Hanna I, Thomas G, Greenspon AJ, Christie M, Goodman J, Christopherson M, Balaji V, Skulsky S, Sanders M, Bauer C, Schindeldecker W, Kirchhof N, and Sohail MR
- Subjects
- Rabbits, Animals, Sheep, Anti-Bacterial Agents pharmacology, Defibrillators, Implantable
- Abstract
Background: The TYRX (Medtronic) absorbable antibacterial envelope has been shown to stabilize implantable cardiac devices and reduce infection. A third-generation envelope was developed to reduce surface roughness with a redesigned multifilament mesh and enhanced form factor but identical polymer coating and antibiotic concentrations as the currently available second-generation envelope., Objective: The purpose of this study was to compare drug elution, bacterial challenge efficacy, stabilization, and absorption of second- vs third-generation envelopes., Methods: Antibiotic elution was assessed in vitro and in vivo. For efficacy against gram-positive/gram-negative bacteria, 40 rabbits underwent device insertions with or without third-generation envelopes. For stabilization (migration, rotation), 5 sheep were implanted with 6 devices each in second- or third-generation envelopes. Prespecified acceptance criteria were <83-mm migration and <90° rotation. Absorption was assessed via gross pathology., Results: Elution curves were equivalent (similarity factors ≥50 per Food and Drug Administration guidance). Third-generation envelopes eluted antibiotics above minimal inhibitory concentration (MIC) in vivo at 2 hours postimplant through 7 days, consistent with second-generation envelopes. Bacterial challenge showed reductions (P <.05) in infection with second- and third-generation envelopes. Device migration was 5.5 ± 3.5 mm (third-generation) vs 9. 9 ±7.9 mm (second-generation) (P <.05). Device rotation was 18.9° ± 11.4° (third-generation) vs 17.6° ± 15.1° (second-generation) and did not differ (P = .79). Gross pathology confirmed the absence of luminal mesh remainders and no differences in peridevice fibrosis at 9 or 12 weeks., Conclusion: The third-generation TYRX absorbable antibacterial envelope demonstrated equivalent preclinical performance to the second-generation envelope. Antibiotic elution curves were similar, elution was above MIC for 7 days, infections were reduced compared to no envelope, and acceptance criteria for migration, rotation, and absorption were met., (Copyright © 2023 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
12. Performance of a cell-free DNA prenatal screening test, choice of prenatal procedure, and chromosome conditions identified during pregnancy after low-risk cell-free DNA screening.
- Author
-
Scarff KL, Flowers N, Love CJ, Archibald AD, Hunt CE, Giouzeppos O, Elliott J, Delatycki MB, and Pertile MD
- Subjects
- Pregnancy, Female, Humans, Prenatal Diagnosis methods, Aneuploidy, Sex Chromosome Aberrations, Chromosomes, Trisomy diagnosis, Cell-Free Nucleic Acids, Chromosome Disorders diagnosis
- Abstract
Objectives: To evaluate the performance of cell-free DNA (cfDNA) screening for common fetal aneuploidies, choice of prenatal procedure, and chromosome conditions identified during pregnancy after low-risk cfDNA screening., Method: A single-center prenatal cfDNA screening test was employed to detect trisomies 21, 18, and 13 (T21, T18, T13) and sex chromosome aneuploidies (SCAs). Test performance, choice of prenatal procedure, and cytogenetic results in pregnancies with low-risk cfDNA screening were reviewed., Results: CfDNA screening of 38,289 consecutive samples identified 720 (1.9%) pregnancies at increased risk for aneuploidy. Positive predictive values (PPVs) for high-risk singleton pregnancies were 98.5% (T21), 92.5% (T18) and 55.2% (T13). PPVs for SCAs ranged from 30.6% to 95.2%. Most women elected chorionic villus sampling for prenatal diagnosis of T21, T18 and T13; amniocentesis and/or postnatal testing were commonly chosen for SCAs. Cytogenetic tests from 616 screen-negative pregnancies identified 64 cases (12.7%) with chromosome conditions not detected by cfDNA screening, including triploidy (n = 30) and pathogenic and likely pathogenic copy number variants (n = 34). A further 15 (0.04%) false-negative common aneuploidy results were identified., Conclusions: CfDNA screening was highly accurate for detecting fetal aneuploidy in this general-risk obstetric population. Fetal ultrasound and prenatal diagnostic testing were important in identifying chromosome conditions in pregnancies screened as low-risk., (© 2023 John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
13. Environmental enrichment and exercise housing protocols for mice.
- Author
-
Love CJ, Gubert C, Renoir T, and Hannan AJ
- Subjects
- Mice, Animals, Reproducibility of Results, Housing, Animal
- Abstract
Here, we present a protocol that allows comparison of the effects of the standard home cage, environmentally enriched home cage with additional super-enrichment, and the exercise (running wheels only) home cage in laboratory mice. We first describe the steps to assemble these three types of cages, respectively. We then detail the assembly of super-enrichment arenas, which provide additional stimulation beyond that provided by home-cage enrichment. This protocol can help to improve reproducibility of results from studies involving environmental enrichment and exercise by offering consistent housing conditions between laboratories. For complete details on the use and execution of this protocol, please refer to Gubert et al. (2021)., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
14. Extraction of cardiac implantable electronic device leads from patients with severely reduced ejection fraction: Never say "Never".
- Author
-
Love CJ
- Subjects
- Humans, Device Removal, Heart, Electronics, Defibrillators, Implantable adverse effects, Pacemaker, Artificial
- Published
- 2022
- Full Text
- View/download PDF
15. Microbiota DNA isolation, 16S rRNA amplicon sequencing, and bioinformatic analysis for bacterial microbiome profiling of rodent fecal samples.
- Author
-
Love CJ, Gubert C, Kodikara S, Kong G, Lê Cao KA, and Hannan AJ
- Subjects
- Animals, RNA, Ribosomal, 16S genetics, Rodentia genetics, Bacteria genetics, DNA, Computational Biology, Microbiota
- Abstract
Fecal samples are frequently used to characterize bacterial populations of the gastrointestinal tract. A protocol is provided to profile gut bacterial populations using rodent fecal samples. We describe the optimal procedures for collecting rodent fecal samples, isolating genomic DNA, 16S rRNA gene V4 region sequencing, and bioinformatic analyses. This protocol includes detailed instructions and example outputs to ensure accurate, reproducible results and data visualization. Comprehensive troubleshooting and limitation sections address technical and statistical issues that may arise when profiling microbiota. For complete details on the use and execution of this protocol, please refer to Gubert et al. (2022)., Competing Interests: The authors declare no competing interests., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
16. Radiographic Identification of Cardiac Implantable Electronic Device Manufacturer: Smartphone Pacemaker-ID Application Versus X-ray Logo.
- Author
-
Boyle B, Love CJ, Marine JE, Chrispin J, Barth AS, Rickard JW, Spragg DD, Berger R, Calkins H, and Sinha SK
- Abstract
Radiographic identification of the cardiac implantable electronic device (CIED) manufacturer facilitates urgent interrogation of an unknown CIED. In the past, we relied on visualizing a manufacturer-specific X-ray logo. Recently, a free smartphone application ("Pacemaker-ID") was made available. A photograph of a chest X-ray was subjected to an artificial intelligence (AI) algorithm that uses manufacturer characteristics (canister shape, battery design) for identification. We sought to externally validate the accuracy of this smartphone application as a point-of-care (POC) diagnostic tool, compare on-axis to off-axis photo accuracy, and compare it to X-ray logo visualization for manufacturer identification. We reviewed operative reports and chest X-rays in 156 pacemaker and 144 defibrillator patients to visualize X-ray logos and to test the application with 3 standard (on-axis) and 4 non-standard (off-axis) photos (20° cranial; caudal, leftward, and rightward). Contingency tables were created and chi-squared analyses (P < .05) were completed for manufacturer and CIED type. The accuracy of the application was 91.7% and 86.3% with single and serial application(s), respectively; 80.7% with off-axis photos; and helpful for all manufacturers (range, 85.4%-96.6%). Overall, the application proved superior to the X-ray logo, visualized in 56% overall (P < .0001) but varied significantly by manufacturer (range, 7.7%-94.8%; P < .00001). The accuracy of the Pacemaker-ID application is consistent with reports from its creators and superior to X-ray logo visualization. The accuracy of the application as a POC tool can be enhanced and maintained with further AI training using recent CIED models. Some manufacturers can enhance their X-ray logos by improving placement and design., Competing Interests: The authors report no conflicts of interest for the published content. No funding was provided., (Copyright: © 2022 Innovations in Cardiac Rhythm Management.)
- Published
- 2022
- Full Text
- View/download PDF
17. Faecal microbiota transplant ameliorates gut dysbiosis and cognitive deficits in Huntington's disease mice.
- Author
-
Gubert C, Choo JM, Love CJ, Kodikara S, Masson BA, Liew JJM, Wang Y, Kong G, Narayana VK, Renoir T, Lê Cao KA, Rogers GB, and Hannan AJ
- Abstract
Huntington's disease is a neurodegenerative disorder involving psychiatric, cognitive and motor symptoms. Huntington's disease is caused by a tandem-repeat expansion in the huntingtin gene, which is widely expressed throughout the brain and body, including the gastrointestinal system. There are currently no effective disease-modifying treatments available for this fatal disorder. Despite recent evidence of gut microbiome disruption in preclinical and clinical Huntington's disease, its potential as a target for therapeutic interventions has not been explored. The microbiota-gut-brain axis provides a potential pathway through which changes in the gut could modulate brain function, including cognition. We now show that faecal microbiota transplant (FMT) from wild-type into Huntington's disease mice positively modulates cognitive outcomes, particularly in females. In Huntington's disease male mice, we revealed an inefficiency of FMT engraftment, which is potentially due to the more pronounced changes in the structure, composition and instability of the gut microbial community, and the imbalance in acetate and gut immune profiles found in these mice. This study demonstrates a role for gut microbiome modulation in ameliorating cognitive deficits modelling dementia in Huntington's disease. Our findings pave the way for the development of future therapeutic approaches, including FMT and other forms of gut microbiome modulation, as potential clinical interventions for Huntington's disease., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.)
- Published
- 2022
- Full Text
- View/download PDF
18. Prolonged asystole during REM sleep: A case report and review of the literature.
- Author
-
Sampognaro JR, Barth AS, Jun JC, Chrispin J, Berger RD, Love CJ, Eddy C, and Calkins H
- Published
- 2022
- Full Text
- View/download PDF
19. The microbiota-gut-brain axis in Huntington's disease.
- Author
-
Love CJ, Masson BA, Gubert C, and Hannan AJ
- Subjects
- Humans, Brain-Gut Axis, Brain metabolism, Huntington Disease pathology, Neurodegenerative Diseases pathology, Microbiota
- Abstract
Huntington's disease (HD) is a fatal neurodegenerative disorder caused by an autosomal dominant trinucleotide (CAG) tandem repeat, resulting in complex motor, psychiatric and cognitive symptoms as well as gastrointestinal disturbances and other peripheral symptoms. There are currently no disease-modifying treatments, and the peripheral pathology of the disorder is not well understood. Emerging evidence suggests that the bi-directional communication pathways between the gut and the brain, including the microbiota-gut-brain axis, can affect motor, psychiatric and cognitive symptoms as well as weight loss and sexual dimorphism seen in HD. Furthermore, both HD and the microbiota-gut-brain axis can be influenced by environmental factors, opening potential new avenues to explore therapeutic options for this devastating disorder., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
20. Gene-environment-gut interactions in Huntington's disease mice are associated with environmental modulation of the gut microbiome.
- Author
-
Gubert C, Love CJ, Kodikara S, Mei Liew JJ, Renoir T, Lê Cao KA, and Hannan AJ
- Abstract
Gut dysbiosis in Huntington's disease (HD) has recently been reported using microbiome profiling in R6/1 HD mice and replicated in clinical HD. In HD mice, environmental enrichment (EE) and exercise (EX) were shown to have therapeutic impacts on the brain and associated symptoms. We hypothesize that these housing interventions modulate the gut microbiome, configuring one of the mechanisms that mediate their therapeutic effects observed in HD. We exposed R6/1 mice to a protocol of either EE or EX, relative to standard-housed control conditions, before the onset of gut dysbiosis and motor deficits. We characterized gut structure and function, as well as gut microbiome profiling using 16S rRNA sequencing. Multivariate analysis identified specific orders, namely Bacteroidales, Lachnospirales and Oscillospirales, as the main bacterial signatures that discriminate between housing conditions. Our findings suggest a promising role for the gut microbiome in mediating the effects of EE and EX exposures, and possibly other environmental interventions, in HD mice., Competing Interests: The authors declare no competing interests., (© 2022 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
21. Subcutaneous implantable cardioverter-defibrillator and defibrillation testing: A propensity-matched pilot study.
- Author
-
Forleo GB, Gasperetti A, Breitenstein A, Laredo M, Schiavone M, Ziacchi M, Vogler J, Ricciardi D, Palmisano P, Piro A, Compagnucci P, Waintraub X, Mitacchione G, Carrassa G, Russo G, De Bonis S, Angeletti A, Bisignani A, Picarelli F, Casella M, Bressi E, Rovaris G, Calò L, Santini L, Pignalberi C, Lavalle C, Viecca M, Pisanò E, Olivotto I, Curnis A, Dello Russo A, Tondo C, Love CJ, Di Biase L, Steffel J, Tilz R, Badenco N, and Biffi M
- Subjects
- Comparative Effectiveness Research, Death, Sudden, Cardiac epidemiology, Death, Sudden, Cardiac prevention & control, Europe epidemiology, Female, Humans, Male, Materials Testing methods, Materials Testing statistics & numerical data, Middle Aged, Propensity Score, Risk Assessment methods, Defibrillators, Implantable adverse effects, Defibrillators, Implantable statistics & numerical data, Electric Countershock statistics & numerical data, Equipment Failure statistics & numerical data, Equipment Failure Analysis methods, Equipment Failure Analysis statistics & numerical data, Tachycardia, Ventricular mortality, Tachycardia, Ventricular therapy
- Abstract
Background: To date, only a few comparisons between subcutaneous implantable cardioverter-defibrillator (S-ICD) patients undergoing and those not undergoing defibrillation testing (DT) at implantation (DT+ vs DT-) have been reported., Objective: The purpose of this study was to compare long-term clinical outcomes of 2 propensity-matched cohorts of DT+ and DT- patients., Methods: Among consecutive S-ICD patients implanted across 17 centers from January 2015 to October 2020, DT- patients were 1:1 propensity-matched for baseline characteristics with DT+ patients. The primary outcome was a composite of ineffective shocks and cardiovascular mortality. Appropriate and inappropriate shock rates were deemed secondary outcomes., Results: Among 1290 patients, a total of 566 propensity-matched patients (283 DT+; 283 DT-) served as study population. Over median follow-up of 25.3 months, no significant differences in primary outcome event rates were found (10 DT+ vs 14 DT-; P = .404) as well as for ineffective shocks (5 DT- vs 3 DT+; P = .725). At multivariable Cox regression analysis, DT performance was associated with a reduction of neither the primary combined outcome nor ineffective shocks at follow-up. A high PRAETORIAN score was positively associated with both the primary outcome (hazard ratio 3.976; confidence interval 1.339-11.802; P = .013) and ineffective shocks alone at follow-up (hazard ratio 19.030; confidence interval 4.752-76.203; P = .003)., Conclusion: In 2 cohorts of strictly propensity-matched patients, DT performance was not associated with significant differences in cardiovascular mortality and ineffective shocks. The PRAETORIAN score is capable of correctly identifying a large percentage of patients at risk for ineffective shock conversion in both cohorts., (Copyright © 2021 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
22. Long-term complications in patients implanted with subcutaneous implantable cardioverter-defibrillators: Real-world data from the extended ELISIR experience.
- Author
-
Gasperetti A, Schiavone M, Ziacchi M, Vogler J, Breitenstein A, Laredo M, Palmisano P, Ricciardi D, Mitacchione G, Compagnucci P, Bisignani A, Angeletti A, Casella M, Picarelli F, Fink T, Kaiser L, Hakmi S, Calò L, Pignalberi C, Santini L, Lavalle C, Pisanò E, Olivotto I, Tondo C, Curnis A, Dello Russo A, Badenco N, Steffel J, Love CJ, Tilz R, Forleo G, and Biffi M
- Subjects
- Adult, Death, Sudden, Cardiac etiology, Device Removal, Equipment Failure, Female, Follow-Up Studies, Humans, Incidence, Italy epidemiology, Male, Middle Aged, Time Factors, Death, Sudden, Cardiac epidemiology, Defibrillators, Implantable adverse effects, Registries
- Abstract
Background: Recently, the Food and Drug Administration issued a recall for the subcutaneous implantable cardioverter-defibrillator (S-ICD) because of the possibility of lead ruptures and accelerated battery depletion., Objective: The aim of this study was to evaluate device-related complications over time in a large real-world multicenter S-ICD cohort., Methods: Patients implanted with an S-ICD from January 2015 to June 2020 were enrolled from a 19-institution European registry (Experience from the Long-term Italian S-ICD registry [ELISIR]; ClinicalTrials.gov identifier NCT0473876). Device-related complication rates over follow-up were collected. Last follow-up of patients was performed after the Boston Scientific recall issue., Results: A total of 1254 patients (median age 52.0 [interquartile range 41.0-62.2] years; 973 (77.6%) men; 387 (30.9%) ischemic) was enrolled. Over a follow-up of 23.2 (12.8-37.8) months, complications were observed in 117 patients (9.3%) for a total of 127 device-related complications (23.6% managed conservatively and 76.4% required reintervention). Twenty-seven patients (2.2%) had unanticipated generator replacement after 3.6 (3.3-3.9) years, while 4 (0.3%) had lead rupture. Body mass index (hazard ratio [HR] 1.063 [95% confidence interval 1.028-1.100]; P < .001), chronic kidney disease (HR 1.960 [1.191-3.225]; P = .008), and oral anticoagulation (HR 1.437 [1.010-2.045]; P = .043) were associated with an increase in overall complications, whereas older age (HR 0.980 [0.967-0.994]; P = .007) and procedure performed in high-volume centers (HR 0.463 [0.300-0.715]; P = .001) were protective factors., Conclusion: The overall complication rate over 23.2 months of follow-up in a multicenter S-ICD cohort was 9.3%. Early unanticipated device battery depletions occurred in 2.2% of patients, while lead fracture was observed in 0.3%, which is in line with the expected rates reported by Boston Scientific., (Copyright © 2021 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
23. Use of healthcare claims to validate the Prevention of Arrhythmia Device Infection Trial cardiac implantable electronic device infection risk score.
- Author
-
Ahmed FZ, Blomström-Lundqvist C, Bloom H, Cooper C, Ellis C, Goette A, Greenspon AJ, Love CJ, Johansen JB, Philippon F, Tarakji KG, Holbrook R, Sherfesee L, Xia Y, Seshadri S, Lexcen DR, and Krahn AD
- Subjects
- Adolescent, Adult, Arrhythmias, Cardiac therapy, Delivery of Health Care, Electronics, Humans, Retrospective Studies, Risk Factors, Defibrillators, Implantable adverse effects, Pacemaker, Artificial adverse effects, Prosthesis-Related Infections diagnosis, Prosthesis-Related Infections epidemiology, Prosthesis-Related Infections prevention & control
- Abstract
Aim: The Prevention of Arrhythmia Device Infection Trial (PADIT) infection risk score, developed based on a large prospectively collected data set, identified five independent predictors of cardiac implantable electronic device (CIED) infection. We performed an independent validation of the risk score in a data set extracted from U.S. healthcare claims., Methods and Results: Retrospective identification of index CIED procedures among patients aged ≥18 years with at least one record of a CIED procedure between January 2011 and September 2014 in a U.S health claims database. PADIT risk factors and major CIED infections (with system removal, invasive procedure without system removal, or infection-attributable death) were identified through diagnosis and procedure codes. The data set was randomized by PADIT score into Data Set A (60%) and Data Set B (40%). A frailty model allowing multiple procedures per patient was fit using Data Set A, with PADIT score as the only predictor, excluding patients with prior CIED infection. A data set of 54 042 index procedures among 51 623 patients with 574 infections was extracted. Among patients with no history of prior CIED infection, a 1 unit increase in the PADIT score was associated with a relative 28% increase in infection risk. Prior CIED infection was associated with significant incremental predictive value (HR 5.66, P < 0.0001) after adjusting for PADIT score. A Harrell's C-statistic for the PADIT score and history of prior CIED infection was 0.76., Conclusion: The PADIT risk score predicts increased CIED infection risk, identifying higher risk patients that could potentially benefit from targeted interventions to reduce the risk of CIED infection. Prior CIED infection confers incremental predictive value to the PADIT score., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2021
- Full Text
- View/download PDF
24. Current Guidelines and Clinical Practice.
- Author
-
Love CJ
- Subjects
- Humans, Electrocardiography, Ambulatory
- Abstract
Guidelines exist for monitoring to diagnose and manage patients with several different conditions. Although there have been recent updates to the guidelines, the constantly evolving and advancing nature of the technologies creates a gap at times between the newest monitors, the indications for their use, and the reimbursement by the payers. The key element to the choice of the modality of monitoring remains matching the correct technology to the type, severity, frequency, and duration of the patient's symptoms., Competing Interests: Disclosure Medical Consultant: Medtronic, Philips Image Guided Therapy. Research Support: Boston Scientific. Honoraria: Abbott Medical, Convatec., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
25. Alert-Based ICD Follow-Up: A Model of Digitally Driven Remote Patient Monitoring.
- Author
-
Varma N, Love CJ, Michalski J, and Epstein AE
- Subjects
- Aged, Humans, Male, Middle Aged, Monitoring, Physiologic, Primary Prevention, Stroke Volume, Ambulatory Care, Ventricular Function, Left
- Abstract
Objectives: The goal of this study was to test whether continuous automatic remote patient monitoring (RPM) linked to centralized analytics reduces nonactionable in-person patient evaluation (IPE) but maintains detection of at-risk patients and provides actionable notifications., Background: Conventional ambulatory care requires frequent IPEs. Many encounters are nonactionable, and additional unscheduled IPEs occur., Methods: Patients receiving implantable cardioverter-defibrillators for Class I/IIa indications were randomized (2:1) to RPM or conventional follow-up, and they were followed up for 15 months. IPEs were conducted every 3 months in the conventional care group but at 3 and 15 months with RPM. Groups were compared for patient retention, nonactionable IPEs, and discovery of at-risk patients during 1 year of exclusive RPM. Frequency and value of RPM alerts were assessed., Results: Patients enrolled (mean age 63.5 ± 12.8 years; male 71.9%; left ventricular ejection fraction 29.0 ± 10.7%; primary prevention 72.3%; n = 1450) were similar between groups (977 RPM vs. 473 conventional care). Mean follow-up durations were 407 ± 103 days for the RPM group versus 399 ± 111 days for the conventional care group (p = 0.165). Patient attrition to follow-up was 42% greater with conventional care (20.1% [87 of 431]) versus RPM (14.2% [129 of 908]; p = 0.007). Nonactionable IPEs were reduced 81% by RPM (0.7 per patient year) compared with conventional care (3.6 per patient year; p < 0.001) but event discoveries remained similar (2.9 per patient year). In RPM, alert rate was median 1 per patient (interquartile range: 0 to 3) with >50% actionability, indicating low volume but high clinical value. Unscheduled IPE was the basis for discovery of 100% of intercurrent problems in RPM and also 75% in conventional care, indicating limited value of appointment-based follow-up for problem discovery. The number of IPEs needed to discover an actionable event was 8.2 in Conventional, 4.9 in RPM, and 2.1 when alert driven (p < 0.001)., Conclusions: RPM transformed ambulatory care to IPE directed to those patients with clinically actionable events when required. Filtering patient information by digitally driven remote monitoring expends fewer clinic resources while providing a greater yield of actionable interventions. (Lumos-T Safely Reduces Routine Office Device Follow-up [TRUST]; NCT00336284)., Competing Interests: Funding Support and Author Disclosures This study was sponsored by Biotronik, Inc. Dr. Varma is a consultant/speaker for Abbott, Medtronic, Biotronik, Impulse Dynamics, and Boston Scientific. Dr. Love is a consultant for Medtronic, Biotronik, Abbott, Spectranetics, and ConvaTec. Mr. Michalski is an employee of Biotronik. Dr. Epstein is a consultant to Biotronik and Abbott., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
26. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS).
- Author
-
Burri H, Starck C, Auricchio A, Biffi M, Burri M, D'Avila A, Deharo JC, Glikson M, Israel C, Lau CP, Leclercq C, Love CJ, Nielsen JC, Vernooy K, Dagres N, Boveda S, Butter C, Marijon E, Braunschweig F, Mairesse GH, Gleva M, Defaye P, Zanon F, Lopez-Cabanillas N, Guerra JM, Vassilikos VP, and Martins Oliveira M
- Subjects
- Asia, Consensus, Humans, United States, Defibrillators, Implantable, Pacemaker, Artificial
- Abstract
With the global increase in device implantations, there is a growing need to train physicians to implant pacemakers and implantable cardioverter-defibrillators. Although there are international recommendations for device indications and programming, there is no consensus to date regarding implantation technique. This document is founded on a systematic literature search and review, and on consensus from an international task force. It aims to fill the gap by setting standards for device implantation., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
27. Observation of Collagen-Containing Lesions After Hematoma Resolution in Intracerebral Hemorrhage.
- Author
-
Love CJ, Kirschenbaum D, Selim M, Lo EH, Rushing E, Spector M, and Aguzzi A
- Subjects
- Animals, Brain pathology, Cerebral Hemorrhage pathology, Disease Models, Animal, Female, Glial Fibrillary Acidic Protein metabolism, Gray Matter pathology, Humans, Male, Rats, Rats, Sprague-Dawley, Brain metabolism, Cerebral Hemorrhage metabolism, Collagen metabolism, Gray Matter metabolism
- Abstract
Background and Purpose: The classic presentation of chronic (stage III) hemorrhagic stroke lesions is a fluid-filled cavity. In one of the most commonly used animal models of intracerebral hemorrhage (ICH), we noticed additional solid material within the chronic lesion. We examined the composition of those chronic ICH lesions and compared them with human autopsy cases., Methods: ICH was induced in rats by the injection of collagenase in the striatum. Tissue sections after hematoma resolution corresponding to 3 different chronic time points—28, 42, and 73 to 85 days post-ICH—were selected. Human autopsy reports at the University Hospital of Zurich were searched between 1990 and 2019 for ICH, and 3 chronic cases were found. The rat and human sections were stained with a variety of histopathologic markers., Results: Extensive collagenous material was observed in the chronic lesion after hematoma resolution in both the rat model and human autopsy cases. Additional immunostaining revealed that the material consisted primarily of a loose network of collagen 3 intermingled with occasional GFAP (glial fibrillary acidic protein)-positive processes and collagen 4., Conclusions: A key feature of the chronic ICH lesion is a loose network of collagen 3. The collagenase rat model reproduces the morphology and composition of the chronic human ICH lesion. While identifying new features of ICH lesion pathology, these results are important for treatment and recovery strategies.
- Published
- 2021
- Full Text
- View/download PDF
28. Envelopes on cardiac implantable electronic devices: Aiming at zero.
- Author
-
Love CJ
- Subjects
- Electronics, Humans, Pacemaker, Artificial, Prosthesis-Related Infections
- Published
- 2021
- Full Text
- View/download PDF
29. Genome-wide noninvasive prenatal screening for carriers of balanced reciprocal translocations.
- Author
-
Flowers NJ, Burgess T, Giouzeppos O, Shi G, Love CJ, Hunt CE, Scarff KL, Archibald AD, and Pertile MD
- Subjects
- Female, Heterozygote, Humans, Infant, Newborn, Pregnancy, Prenatal Diagnosis, Retrospective Studies, Translocation, Genetic, Noninvasive Prenatal Testing
- Abstract
Purpose: Balanced reciprocal translocation carriers are at increased risk of producing gametes with unbalanced forms of the translocation leading to miscarriage, fetal anomalies, and birth defects. We sought to determine if genome-wide cell-free DNA based noninvasive prenatal screening (gw-NIPS) could provide an alternative to prenatal diagnosis for carriers of these chromosomal rearrangements., Methods: This pilot series comprises a retrospective analysis of gw-NIPS and clinical outcome data from 42 singleton pregnancies where one parent carried a balanced reciprocal translocation. Gw-NIPS was performed between August 2015 and March 2018. Inclusion criteria required at least one translocation segment to be ≥15 Mb in size., Results: Forty samples (95%) returned an informative result; 7 pregnancies (17.5%) were high risk for an unbalanced translocation and confirmed after diagnostic testing. The remaining 33 informative samples were low risk and confirmed after diagnostic testing or normal newborn physical exam. Test sensitivity of 100% (95% confidence interval [CI]: 64.6-100%) and specificity of 100% (95% CI: 89.6-100%) were observed for this pilot series., Conclusion: We demonstrate that gw-NIPS is a potential option for a majority of reciprocal translocation carriers. Further confirmation of this methodology could lead to adoption of this noninvasive alternative.
- Published
- 2020
- Full Text
- View/download PDF
30. Left Ventricular Enlargement, Cardiac Resynchronization Therapy Efficacy, and Impact of MultiPoint Pacing.
- Author
-
Varma N, Baker J 2nd, Tomassoni G, Love CJ, Martin D, Sheppard R, Niazi I, Cranke G, Lee K, and Corbisiero R
- Subjects
- Aged, Female, Heart Failure diagnosis, Heart Failure mortality, Heart Failure physiopathology, Humans, Hypertrophy, Left Ventricular diagnostic imaging, Hypertrophy, Left Ventricular mortality, Male, Middle Aged, Quality of Life, Randomized Controlled Trials as Topic, Recovery of Function, Retrospective Studies, Time Factors, Treatment Outcome, United States, Cardiac Resynchronization Therapy adverse effects, Cardiac Resynchronization Therapy mortality, Heart Failure therapy, Heart Rate, Hypertrophy, Left Ventricular physiopathology, Ventricular Function, Left, Ventricular Remodeling
- Abstract
Background: Left ventricular (LV) epicardial pacing results in slowly propagating paced wavefronts. We postulated that this effect might limit cardiac resynchronization therapy efficacy in patients with LV enlargement using conventional biventricular pacing with single-site LV pacing, but be mitigated by LV stimulation from 2 widely spaced sites using MultiPoint pacing with wide anatomic separation (MPP-AS: ≥30 mm). We tested this hypothesis in the multicenter randomized MPP investigational device exemption trial., Methods: Following implant, quadripolar biventricular single-site pacing was activated in all patients (n=506). From 3 to 9 months postimplant, among patients with available baseline LV end-diastolic volume (LVEDV) measures, 188 received biventricular single-site pacing and 43 received MPP-AS. Patients were dichotomized by median baseline LVEDV indexed to height (LVEDVI
Median ). Outcomes were measured by the clinical composite score (primary efficacy end point), quality of life, LV structural remodeling (↑EF >5% and ↓ESV 10%) and heart failure event/cardiovascular death., Results: LVEDVIMedian was 1.1 mL/cm. Baseline characteristics differed in patients with LVEDVI>Median versus LVEDVI≤Median . Among patients with LVEDVI>Median , biventricular single-site pacing was less efficacious compared to patients with LVEDVI≤Median (clinical composite score, 65% versus 79%). In contrast, MPP-AS programming generated greater clinical composite score response (92% versus 65%, P =0.023) and improved quality of life (-31.0±29.7 versus -15.7±22.1, P =0.038) versus biventricular single-site pacing in patients with LVEDVI>Median . Reverse remodeling trended better with MPP-AS programming. In patients with LVEDVI>Median , heart failure event rate increased following the 3-month randomization point with biventricular single-site pacing (0.0150±0.1725 in LVEDVI>Median versus -0.0190±0.0808 in LVEDVI≤Median , P =0.012), but no heart failure event occurred in patients with MPP-AS programming between 3 and 9 months in LVEDVI>Median . All measured outcomes did not differ in patients receiving MPP-AS and biventricular single-site pacing with LVEDVI≤Median ., Conclusions: Conventional biventricular single-site pacing, even with a quadripolar lead, has reduced efficacy in patients with LV enlargement. However, the greatest response rate in patients with larger hearts was observed when programmed to MPP-AS pacing.- Published
- 2020
- Full Text
- View/download PDF
31. Mechanism of spontaneous initiation of ventricular fibrillation in patients with implantable defibrillators.
- Author
-
Xie E, Mayer K, Capps MF, Barth AS, Love CJ, Coronel R, and Ashikaga H
- Subjects
- Cross-Sectional Studies, Humans, Tachycardia, Ventricular diagnosis, Tachycardia, Ventricular therapy, Ventricular Premature Complexes diagnosis, Defibrillators, Implantable, Ventricular Fibrillation diagnosis, Ventricular Fibrillation therapy
- Abstract
Introduction: To improve the mechanistic understanding of spontaneous initiation of ventricular fibrillation (VF), we characterized the patterns of premature ventricular complex (PVC) preceding spontaneous VF in primary and secondary implantable cardioverter-defibrillator (ICD) recipients., Methods and Results: A single-center, cross-sectional analysis of 1209 patients with primary and secondary prevention ICD identified 190 patients who received ICD therapy (firing or antitachycardia pacing) for VF or monomorphic ventricular tachycardia (MMVT). Initiation was quantified by the coupling interval (CI), the cycle length immediately preceding the CI (CL(-1)), the CI corrected by CL(-1) using Fridericia's formula (CIc), and the prematurity index (PI). In both VF (n = 44; 23%) and MMVT (n = 134; 71%), the most common pattern of initiation was late-coupled PVC, followed by the short-long-short pattern. The parameters such as pre-initiation median CL, CL(-1), CI, and PI were not significantly different between VF and MMVT for any patterns. At least some events (45% of VF and 63% of MMVT) had extremely long CIs beyond the QTc cut-off estimated from the CL(-1), suggestive of initiation by a train of multiple PVCs or nonsustained VT instead of a single PVC., Conclusion: Some spontaneous VF events in ICD recipients appear to be initiated by a train of multiple PVC or nonsustained VT rather than a single PVC. This finding indicates that patterns of a single PVC are not an important determinant of VF initiation and thus account for conflicting results in previous studies., (© 2020 Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
32. Salvage of an epicardial lead in a pacemaker-dependent patient with Fontan palliation using an IS-1 extender.
- Author
-
Aronis KN, Mettler BA, Love CJ, and de la Uz CM
- Subjects
- Adult, Cardiac Pacing, Artificial, Humans, Male, Pericardium surgery, Sick Sinus Syndrome therapy, Fontan Procedure adverse effects, Pacemaker, Artificial
- Abstract
We present a case report of severed epicardial atrial lead salvage using an IS-1 lead extender. A 37-year-old male with single ventricle physiology, Fontan palliation, sinus node dysfunction, recurrent atrial tachycardias, and atrial fibrillation resulting in failing Fontan physiology presented with failure of the atrial pacing lead. The patient was initially paced with an epicardial system that had to be removed due to pocket infection, and the epicardial leads were cut and abandoned. Given his significant sinus node dysfunction he required atrial pacing to allow for rhythm control. The failing Fontan physiology of the patient precluded him from undergoing surgery for epicardial lead placement or a complex intravascular lead placement procedure (although anatomically feasible). We considered the option of salvaging the existing epicardial atrial leads to provide atrial pacing, allowing for rhythm control and improvement of his failing Fontan physiology as a bridge to a more permanent pacing solution. This case report is important because it demonstrates how a lead extender can be used to salvage a severed pacemaker lead. This may be useful for patients in whom implantation of new leads is not promptly feasible due to patient anatomy and/or clinical status., (© 2020 Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
33. Managing cardiac implantable electronic device patients during a health care crisis: Practical guidance.
- Author
-
Sinha SK, Akinyele B, Spragg DD, Marine JE, Berger R, Calkins H, and Love CJ
- Abstract
Our world is faced with a global pandemic that threatens to overwhelm many national health care systems for a prolonged period. Consequently, the elective long-term cardiac implantable electronic device (CIED) management of millions of patients is potentially compromised, raising the likelihood of patients experiencing major adverse events owing to loss of CIED therapy. This review gives practical guidance to health care providers to help promptly recognize the requirement for expert consultation for urgent interrogation and/or surgery in CIED patients., (© 2020 Heart Rhythm Society. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
34. Blood use for transvenous lead extractions at a high-volume center.
- Author
-
Cho BC, Nyhan S, Merkel KR, Hensley NB, Gehrie EA, Choi CW, Love CJ, and Frank SM
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Anemia blood, Anemia therapy, Continuous Renal Replacement Therapy, Databases, Factual, Defibrillators, Implantable, Erythrocyte Transfusion, Lead blood, Preoperative Care
- Abstract
Background: Transvenous lead extractions (TLEs) have increased in number due to an increased prevalence of cardiac implantable devices. Bleeding complications associated with TLEs can be catastrophic, and many institutions order blood components to be available in the procedure room. There are few studies supporting or refuting this practice. We evaluated transfusion rates for TLEs at a single, high-volume center to assess the need for having blood in the procedure room., Study Design and Methods: Patients undergoing TLEs from April 2010 to February 2019 were identified from our institutional database. The percentage of patients transfused intraoperatively, the number of units transfused, and the reasons for transfusion were determined from the database and by manual chart review., Results: A total of 473 patients underwent a TLE during this time frame. Of these, only 17 patients (3.6%) received a red blood cell (RBC) transfusion. Ten of the 17 patients received RBCs secondary to preoperative anemia. Of the remaining seven patients, only four patients received more than 2 RBC units, and only one received more than 10 RBC units. No patient received more than 2 RBC units or any plasma or platelets in the past 4 years., Conclusion: Due to improvements in procedural techniques, advent of accessible remote blood allocation systems, and changes in transfusion practice (e.g., electronic crossmatch), routinely having blood components in the procedure room for every TLE may be an outdated practice for high-volume centers., (© 2020 AABB.)
- Published
- 2020
- Full Text
- View/download PDF
35. Electrocardiographic predictors of pacemaker battery depletion: Diagnostic sensitivity, specificity, and clinical risk.
- Author
-
Carlson D, Marine JE, Love CJ, Chrispin J, Barth AS, Rickard JJ, Spragg DD, Berger R, Calkins H, Tomaselli GF, and Sinha SK
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Predictive Value of Tests, Retrospective Studies, Sensitivity and Specificity, Electric Power Supplies, Electrocardiography methods, Equipment Failure, Pacemaker, Artificial
- Abstract
Background: Pacemaker battery depletion triggers alert for replacement notification and results in automatic reprogramming, which has been shown to be associated with relevant cardiorespiratory symptoms and adverse clinical events., Objective: Determine if electrocardiogram (ECG) pacing features may be predictive of pacemaker battery depletion and clinical risk., Methods: This is an ECG substudy of a cohort analysis of 298 subjects referred for pacemaker generator replacement from 2006 to 2017. Electronic medical record review was performed; clinical, ECG, and pacemaker characteristics were abstracted. We applied two ECG prediction rules for pacemaker battery depletion that are relevant to all major pacemaker manufacturers except Boston Scientific and MicroPort: (1) atrial pacing not at a multiple of 10 and (2) nonsynchronous ventricular pacing not at a multiple of 10, to determine diagnostic sensitivity, specificity, and risk in applicable ECG subjects., Results: We excluded 32 subjects not at replacement notification or duplicate surgeries. Overall, 176 of 266 subjects (66.2%) demonstrated atrial pacing or nonsynchronous ventricular pacing on preoperative ECG. When utilizing both rules, 139 of 176 preoperative ECGs and 12 of 163 postoperative ECGs met criteria for battery depletion yielding reasonable sensitivity (79.0%), high specificity (92.6%), and a positive likelihood ratio of 11.6:1. These rules were associated with significant increase in cardiorespiratory symptoms (P < .001) and adverse clinical events (P < .025)., Conclusions: The "Rules of Ten" provided reasonable sensitivity and specificity for detecting replacement notification in pacemaker subjects with an applicable ECG. This ECG tool may help clinicians identify most patients with pacemaker battery depletion at significant clinical risk., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
36. Early diagnosis of Pearson syndrome in neonatal intensive care following rapid mitochondrial genome sequencing in tandem with exome sequencing.
- Author
-
Akesson LS, Eggers S, Love CJ, Chong B, Krzesinski EI, Brown NJ, Tan TY, Richmond CM, Thorburn DR, Christodoulou J, Hunter MF, Lunke S, and Stark Z
- Subjects
- Acyl-CoA Dehydrogenase, Long-Chain genetics, Congenital Bone Marrow Failure Syndromes diagnosis, DNA, Mitochondrial genetics, Exome genetics, Female, Genetic Testing, Humans, Infant, Newborn, Intensive Care, Neonatal, Lipid Metabolism, Inborn Errors diagnosis, Male, Mitochondria genetics, Mitochondrial Diseases diagnosis, Muscular Diseases diagnosis, Exome Sequencing standards, Whole Genome Sequencing, Acyl-CoA Dehydrogenase, Long-Chain deficiency, Congenital Bone Marrow Failure Syndromes genetics, Early Diagnosis, Genome, Mitochondrial genetics, Lipid Metabolism, Inborn Errors genetics, Mitochondrial Diseases genetics, Muscular Diseases genetics
- Abstract
Rapid genomic testing is a valuable new diagnostic tool for acutely unwell infants, however exome sequencing does not deliver clinical-grade mitochondrial genome sequencing and may fail to diagnose mitochondrial disorders caused by mitochondrial DNA (mtDNA) variants. Rapid mitochondrial genome sequencing and analysis are not routinely available in rapid genomic diagnosis programmes. We present two critically ill neonates with transfusion-dependent anaemia and persistent lactic acidosis who underwent rapid mitochondrial genome sequencing in tandem with exome sequencing as part of an exome sequencing-based rapid genomic diagnosis programme. No diagnostic variants were identified on examination of the nuclear exome data for either infant. Mitochondrial genome sequencing identified a large mtDNA deletion in both infants, diagnosing Pearson syndrome within 74 and 55 h, respectively. Early diagnosis in the third week of life allowed the avoidance of a range of other investigations and appropriate treatment planning. Rapid mitochondrial genome analysis provides additional diagnostic and clinical utility and should be considered as an adjunct to exome sequencing in rapid genomic diagnosis programmes.
- Published
- 2019
- Full Text
- View/download PDF
37. Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study.
- Author
-
Kondrashova O, Ho GY, Au-Yeung G, Leas L, Boughtwood T, Alsop K, Zapparoli G, Dobrovic A, Ko YA, Hsu AL, Love CJ, Lunke S, Wakefield MJ, McNally O, Quinn M, Ananda S, Neesham D, Hamilton A, Grossi M, Freimund A, Kanjanapan Y, Rischin D, Traficante N, Bowtell D, Scott CL, Christie M, Taylor GR, Mileshkin L, and Waring PM
- Abstract
Purpose: The ALLOCATE study was designed as a pilot to demonstrate the feasibility and clinical utility of real-time targeted molecular profiling of patients with recurrent or advanced ovarian cancer for identification of potential targeted therapies., Patients and Methods: A total of 113 patients with ovarian cancer of varying histologies were recruited from two tertiary hospitals, with 99 patient cases suitable for prospective analysis. Targeted molecular and methylation profiling of fresh biopsy and archived tumor samples were performed by screening for mutations or copy-number variations in 44 genes and for promoter methylation of BRCA1 and RAD51C ., Results: Somatic genomic or methylation events were identified in 85% of all patient cases, with potentially actionable events with defined targeted therapies (including four resistance events) detected in 60% of all patient cases. On the basis of these findings, six patients received molecularly guided therapy, three patients had unsuspected germline cancer-associated BRCA1 / 2 mutations and were referred for genetic counseling, and two intermediate differentiated (grade 2) serous ovarian carcinomas were reclassified as low grade, leading to changes in clinical management. Additionally, secondary reversion mutations in BRCA1 / 2 were identified in fresh biopsy samples of two patients, consistent with clinical platinum/poly (ADP-ribose) polymerase inhibitor resistance. Timely reporting of results if molecular testing is done at disease recurrence, as well as early referral for patients with platinum-resistant cancers, were identified as factors that could improve the clinical utility of molecular profiling., Conclusion: ALLOCATE molecular profiling identified known genomic and methylation alterations of the different ovarian cancer subtypes and was deemed feasible and useful in routine clinical practice. Better patient selection and access to a wider range of targeted therapies or clinical trials will further enhance the clinical utility of molecular profiling.
- Published
- 2019
- Full Text
- View/download PDF
38. Computed Tomography Imaging Before Lead Extraction: Is it Worth the Look?
- Author
-
Chrispin J and Love CJ
- Subjects
- Pacemaker, Artificial, Tomography, X-Ray Computed
- Published
- 2019
- Full Text
- View/download PDF
39. Mechanistic insights into silk fibroin's adhesive properties via chemical functionalization of serine side chains.
- Author
-
Love CJ, Serban BA, Katashima T, Numata K, and Serban MA
- Abstract
Bombyx mori -derived silk fibroin (SF) has recently gained interest for its intrinsic or engineered adhesive properties. In a previous study by our group, the mechanism of the protein's intrinsic adhesiveness to biological substrates such as leather has been hypothesized to rely on hydrogen bond formation between amino acid side chains of SF and the substrate. In this study, the serine side chains of SF were chemically functionalized with substituents with different hydrogen bonding abilities. The effect of these changes on adhesion to leather was investigated along with protein structural assessments. The results confirm our hypothesis that adhesive interactions are mediated by hydrogen bonds and indicate that the length and nature of the side chains are important for both adhesion and secondary structure formation.
- Published
- 2019
- Full Text
- View/download PDF
40. RIsk Stratification prior to lead Extraction and impact on major intraprocedural complications (RISE protocol).
- Author
-
Afzal MR, Daoud EG, Matre N, Shoben A, Burnside M, Gilliam C, Pinkhas D, Okabe T, Tyler J, Houmsse M, Kalbfleisch SS, Crestanello JA, Turner K, Weiss R, Hummel JD, Love CJ, and Augostini RS
- Subjects
- Aged, Aged, 80 and over, Databases, Factual, Device Removal mortality, Female, Hospitals, High-Volume, Humans, Male, Middle Aged, Ohio, Postoperative Complications mortality, Prospective Studies, Prosthesis Design, Quality Improvement, Quality Indicators, Health Care, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Clinical Protocols, Defibrillators, Implantable, Device Removal adverse effects, Pacemaker, Artificial, Postoperative Complications prevention & control
- Abstract
Background: An internal risk stratification algorithm was developed to decrease the risk of major adverse cardiac events (MACEs) during lead extractions (LEs)., Objective: To report upon the impact of a risk stratification algorithm (RISE [RIsk Stratification prior to lead Extraction] protocol) on outcomes of LEs in a high-volume center., Methods: A retrospective review of a prospectively maintained LEs database was performed to identify features associated with MACEs. On the basis of the retrospective data, the RISE protocol differentiated LEs procedures into "High" and "Low" risk for occurrence of MACEs. High-risk LEs included dual-coil defibrillator lead (≥3 years), pacemaker and single-coil lead (≥5 years), and any StarFix coronary sinus lead. During the prospective evaluation of the RISE protocol, "High-risk" LEs were performed in an operating room (OR) or hybrid laboratory with the cardiac anesthesiologist, OR nursing team, perfusionist in the room, and a cardiac surgeon on the premises. "Low-risk" LEs were performed in the electrophysiology (EP) laboratory with anesthesia provided by EP nursing team. The preintervention (pre-RISE) and postintervention (post-RISE) group spanned 19 and 40 months and consisted of 449 (632 leads) and 751 patients (1055 leads), respectively. The primary outcome of MACEs in the two groups was compared., Results: Protocol compliance was 100%. The primary outcome of MACEs occurred in 15 patients (3.34%) before and 12 (1.6%) after implementation of the RISE protocol (P = .04)., Conclusion: RISE identified a low-risk group where minimal resources are needed and allowed for rapid intervention in the high-risk group that reduced the consequences of MACEs., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
41. Biomaterials for Stroke Therapy.
- Author
-
Love CJ, Selim M, Spector M, and Lo EH
- Subjects
- Humans, Hydrogels, Biocompatible Materials, Stroke therapy
- Published
- 2019
- Full Text
- View/download PDF
42. Intermittent high impedance from the lead-device compatibility problem.
- Author
-
Tanawuttiwat T, Berger RD, and Love CJ
- Subjects
- Adult, Aged, Equipment Failure Analysis, Fatal Outcome, Female, Humans, Male, Middle Aged, Cardiomyopathies therapy, Defibrillators, Implantable, Electric Impedance
- Published
- 2019
- Full Text
- View/download PDF
43. Lead extraction in patients with cardiac resynchronization therapy devices: are they worse than the others?
- Author
-
Monfredi O and Love CJ
- Subjects
- Cardiac Resynchronization Therapy Devices, Device Removal, Humans, Cardiac Resynchronization Therapy, Heart Failure
- Published
- 2019
- Full Text
- View/download PDF
44. Transseptal puncture facilitated by "reverse tenting" using a left atrial ablation catheter.
- Author
-
Habibi M, Cooper JM, Love CJ, and Sinha SK
- Published
- 2018
- Full Text
- View/download PDF
45. Palliation and Nonextraction Approaches.
- Author
-
Love CJ
- Subjects
- Humans, Defibrillators, Implantable adverse effects, Device Removal, Pacemaker, Artificial adverse effects, Palliative Care, Prosthesis-Related Infections
- Abstract
Although definitive therapy for infected cardiac implantable electronic device systems requires removal of all hardware in the infected areas with extraction of intravascular components as well, there are situations where extraction is not available or appropriate. Palliative procedures and chronic suppressive antibiotics may be used in these cases. There are also options that may in some cases result in long-term freedom from infection., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
46. Failure to shock: What is the mechanism?
- Author
-
Torbey E and Love CJ
- Subjects
- Algorithms, Equipment Failure Analysis, Humans, Male, Tachycardia, Ventricular physiopathology, Young Adult, Defibrillators, Implantable adverse effects, Tachycardia, Ventricular therapy
- Abstract
Background: The Biotronik DX lead is an attractive option due to its floating atrial bipole and its noninferiority compared to dual-chamber defibrillators., Methods: We describe the case of atrial undersensing by the DX lead resulting in failure of the device to appropriately treat a slow ventricular tachycardia., Conclusion: This case underlies the importance of understanding the limitations to each lead technology as well as the underlying assumptions inherent to detection enhancement algorithms., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
47. Automatic remote monitoring utilizing daily transmissions: transmission reliability and implantable cardioverter defibrillator battery longevity in the TRUST trial.
- Author
-
Varma N, Love CJ, Schweikert R, Moll P, Michalski J, and Epstein AE
- Subjects
- Automation, Electric Countershock adverse effects, Equipment Design, Equipment Failure, Humans, Predictive Value of Tests, Prospective Studies, Reproducibility of Results, Time Factors, Treatment Outcome, United States, Defibrillators, Implantable, Electric Countershock instrumentation, Electric Power Supplies, Electrophysiologic Techniques, Cardiac instrumentation, Telemedicine instrumentation, Telemetry instrumentation
- Abstract
Aims: Benefits of automatic remote home monitoring (HM) among implantable cardioverter defibrillator (ICD) patients may require high transmission frequency. However, transmission reliability and effects on battery longevity remain uncertain. We hypothesized that HM would have high transmission success permitting punctual guideline based follow-up, and improve battery longevity. This was tested in the prospective randomized TRUST trial., Methods and Results: Implantable cardioverter defibrillator patients were randomized post-implant 2:1 to HM (n = 908) (transmit daily) or to Conventional in-person monitoring [conventional management (CM), n = 431 (HM disabled)]. In both groups, five evaluations were scheduled every 3 months for 15 months. Home Monitoring technology performance was assessed by transmissions received vs. total possible, and number of scheduled HM checks failing because of missed transmissions. Battery longevity was compared in HM vs. CM at 15 months, and again in HM 3 years post-implant using continuously transmitted data. Transmission success per patient was 91% (median follow-up of 434 days). Overall, daily HM transmissions were received in 315 795 of a potential 363 450 days (87%). Only 55/3759 (1.46%) of unsuccessful scheduled evaluations in HM were attributed to transmission loss. Shock frequency and pacing percentage were similar in HM vs. CM. Fifteen month battery longevity was 12% greater in HM (93.2 ± 8.8% vs. 83.5 ± 6.0% CM, P < 0.001). In extended follow-up of HM patients, estimated battery longevity was 50.9 ± 9.1% (median 52%) at 36 months., Conclusion: Automatic remote HM demonstrated robust transmission reliability. Daily transmission load may be sustained without reducing battery longevity. Home Monitoring conserves battery longevity and tracks long term device performance., Clinical Trial Registration: ClinicalTrials.gov; NCT00336284.
- Published
- 2018
- Full Text
- View/download PDF
48. Lead Management and Lead Extraction.
- Author
-
Love CJ
- Subjects
- Humans, Defibrillators, Implantable adverse effects, Device Removal methods, Pacemaker, Artificial adverse effects, Prosthesis-Related Infections surgery
- Abstract
Management of patients with cardiac implantable electronic devices (CIEDs) has become complex given the complications that can occur with implanted lead systems. Clinical problems such as infection, lead failure, and occluded vessels create situations that demand intervention to remove leads. Due to adhesions that occur in the venous system and at the endomyocardial attachment site, simple traction to remove a lead is often not sufficient. Infection is a mandatory reason to remove the entire CIED system. Tools and techniques are now available that enable a skilled operator to extract leads with a great deal of efficacy and safety., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
49. Cardiac Implantable Electronic Device Infections and Lead Extraction: Are Patients With Renal Insufficiency Special?
- Author
-
Chrispin J and Love CJ
- Subjects
- Humans, Renal Dialysis, Defibrillators, Implantable, Pacemaker, Artificial, Renal Insufficiency, Renal Insufficiency, Chronic
- Published
- 2018
- Full Text
- View/download PDF
50. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction.
- Author
-
Kusumoto FM, Schoenfeld MH, Wilkoff BL, Berul CI, Birgersdotter-Green UM, Carrillo R, Cha YM, Clancy J, Deharo JC, Ellenbogen KA, Exner D, Hussein AA, Kennergren C, Krahn A, Lee R, Love CJ, Madden RA, Mazzetti HA, Moore JC, Parsonnet J, Patton KK, Rozner MA, Selzman KA, Shoda M, Srivathsan K, Strathmore NF, Swerdlow CD, Tompkins C, and Wazni O
- Subjects
- Congresses as Topic, Humans, Arrhythmias, Cardiac therapy, Cardiac Resynchronization Therapy Devices, Cardiology, Consensus, Device Removal standards, Disease Management, Societies, Medical
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.